BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE met all primary endpoints, demonstrating...